ArticleActa orthopaedica et traumatologica turcica2025
Total femoral replacement for oncologic indications: Functional outcomes, complications, and implant survival rates.
Article in Acta orthopaedica et traumatologica turcica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTotal femoral replacements for oncological indications are a rare indication, and there is limited data on functional outcomes, complications, and implant survival rates. The purpose of this study was to investigate functional outcomes, the rate and nature of com plications associated with this technique, and the survival rates of the implant used.
methodsThis is a retrospective case series from a single subspeciality orthopedic oncology unit in an urban referral center that evalu ated patients treated between January 2000 and May 2023. A total of 27 patients were included in the final analyses. The Musculoskeletal Tumor Society (MSTS) scoring system was used for functional evaluation. The received adjuvant-neoadjuvant chemotherapies and radio therapies, resected soft tissues during index surgery, complications, the number and extent of secondary surgical interventions, and data on local recurrence were recorded through chart review. Data on implant loss for any reason was also recorded. Complication-freesurvival rate and implant- loss-free survival rate were calculated using the Kaplan-Meier estimator at 60 months. The Henderson clas sification system was used to categorize failure modes.
resultsThe median MSTS score at the most recent follow-up was 21 (range: 17-23). A total of 16 complications occurred in 13 patients. Only one of these complications was an intraoperative issue. Ten of the 16 complications necessitated one or more secondary surgical interventions. The most common complication was infection, occurring in 8 patients. Other complications included hip pain that neces sitated total hip arthroplasty, leg-length discrepancy, and spontaneous patella fractures, each occurring in 2 patients. At 60 months, 10 patients (37%) experienced complications. The mean estimated complication-free survival was 39 months (95% CI: 29-49). There were 6 patients in total who experienced implant loss. Infection was the sole cause of implant loss in 4 patients. Implant loss occurred in 1 patient due to recurrence and in another patient due to a combination of recurrence and infection, which led to amputation in both cases. The mean estimated implant-loss-free survival was 50 months (95% CI: 42-58).
conclusionTotal femoral replacement is reserved for distinctly specific oncological indications, where other more biological reconstruction methods are not feasible. This technique could yield satisfactory functional outcomes, along with a favorable implant survival rate and complication-free survival rate at mid-term. Infection remains the most common complication associated with this technique, while the main causes of implant failure are infection and local recurrence. Future studies focusing on strategies to prevent such complications and define clearer patient selection criteria may substantially improve the overall success of this technique. Cite this article as: Kaya H, Vahabi A, Daştan AE, Çolak TS, Keçeci B, Sabah D. Total femoral replacement for oncologic indications: Functional outcomes, complications, and implant survival rates. Acta Orthop Traumatol Turc., 2025;59(6):477-484.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.